RecruitingNCT06430814
Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
Sponsor
University of Southern Denmark
Enrollment
188 participants
Start Date
Oct 10, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Investigation of which patients treated with paclitaxel have an increased risk of developing peripheral neuropathy.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria6
- Age > 18 years
- Willing to give informed consent
- Scheduled to receive neo-adjuvant or adjuvant paclitaxel treatment
- Able to speak and understand Danish
- Diagnosed with breast cancer
- Paclitaxel naïve patients
Exclusion Criteria10
- Neurodegenerative diseases (e.g., neuropathy from another cause, previous apoplexy, disc herniation
- Type 1 or 2 diabetes
- Pregnant
- Breastfeeding
- Relapse of cancer diagnosis
- Diagnosed with human immunodeficiency virus (HIV)
- Participation in other clinical trials where the dose of paclitaxel is changed, or the aim is to prevent neuropathic pain or decrease NFL level (except if the intervention is to use cooling gloves).
- Previous treatment with neurotoxic chemotherapy
- Chronic pain from another cause
- Metastatic cancer
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo intervention
No intervention
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06430814
Related Trials
Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy
NCT069453801 location
The Role of TRP Channels in CIPN
NCT044158921 location
Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy
NCT075584471 location
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
NCT063897211 location
Cryocompression for CIPN
NCT070647981 location